Market Place
Sourcing Support
ProMIS Neurosciences Announces 2024 Financial Results
31 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents Preclinical Data at 2025 Conference
24 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neuroscience Presents Preclinical Data on Vaccines at Meeting
13 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences at 37th Annual Roth Conference
11 Mar 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences doses first patients in Phase 1b trial for AD
25 Feb 2025 //
GLOBENEWSWIRE
ProMIS Neuro to Participate in Guggenheim Cap Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Issues Letter to Shareholders
13 Jan 2025 //
GLOBENEWSWIRE
Promis Neurosciences Starts Phase 1b Precise-Ad Alzheimer’s Trial
10 Jan 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences to Attend Evercore HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Reports Q3 2024 Financial Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Join Guggenheim Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents PMN310 Alzheimer’s Data
30 Oct 2024 //
GLOBENEWSWIRE
ProMIS To Showcase PMN310 At Cognitive & Behavioral Neurosciences Conference
12 Sep 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences To Present At H.C. Wainwright Conference
05 Sep 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Q2 2024 Results And Recent Highlights
08 Aug 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces ALS Data Publication
06 Aug 2024 //
GLOBENEWSWIRE
ProMIS To Participate In BTIG Virtual Biotechnology Conference
01 Aug 2024 //
GLOBENEWSWIRE
ProMIS Presents Novel Alzheimer`s Vaccine Approach At AAIC 2024
30 Jul 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26 Jul 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Reports Positive Phase 1a Alzheimer`s Trial Data
26 Jul 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Q1 2024 Results, Highlights
14 May 2024 //
GLOBENEWSWIRE
ProMIS Study on Amyloid-Beta Oligomer Selective Antibodies
30 Apr 2024 //
GLOBENEWSWIRE
ProMIS Publishes ALS Treatment Research in Journal of Biological Chemistry
09 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
04 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
11 Mar 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
22 Feb 2024 //
GLOBENEWSWIRE
ProMIS Neuro Achieves Milestone in Development of Alpha-Synuclein Vaccine
22 Jan 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Issues Letter to Shareholders
08 Jan 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Publication on Novel Target for ALS
20 Dec 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310
20 Nov 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
08 Sep 2023 //
GLOBENEWSWIRE
ProMIS to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
21 Aug 2023 //
GLOBENEWSWIRE
ProMIS Announces Second Quarter 2023 Financial Results and Recent Highlights
14 Aug 2023 //
GLOBENEWSWIRE
ProMIS Showcases Data at Alzheimers Association International Conference 2023
17 Jul 2023 //
GLOBENEWSWIRE
ProMIS Announces Completion of Continuance
14 Jul 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
10 Jul 2023 //
GLOBENEWSWIRE
ProMIS Holds Annual Meeting of Shareholders All Resolutions Approved
30 Jun 2023 //
GLOBENEWSWIRE
Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29
29 Jun 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces 1Q 2023 FYR Results and Recent Highlights
15 May 2023 //
GLOBENEWSWIRE
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine
25 Apr 2023 //
GLOBENEWSWIRE
ProMIS Presents Preclinical Highlighting Targeting Toxic Misfolded Proteins
24 Apr 2023 //
GLOBENEWSWIRE
ProMIS Announces Submission of IND Application for Lead Antibody PMN310
10 Apr 2023 //
GLOBENEWSWIRE
Lead Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers
29 Mar 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
13 Mar 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Abstracts Accepted for Presentation
13 Mar 2023 //
GLOBENEWSWIRE
Promis Neuro to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces 3Q 2022 Financial Results and Recent Highlights
14 Nov 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement
12 Oct 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Second Quarter 2022 Financial
15 Aug 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at 2022 AAIC
27 Jul 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN"
08 Jul 2022 //
GLOBENEWSWIRE
Promis Announces Reverse Share Split To Meet Nasdaq Listing Criteria
27 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Debt Amendment and Conversion
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
17 May 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces First Quarter 2022 Results
13 May 2022 //
GLOBENEWSWIRE
